Aclarion, Inc. (ACONW) 股票分析

公司概述

Aclarion, Inc. operates as a healthcare technology company within the United States, leveraging magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments through its NOCISCAN technology. Although the specific sector and industry classifications are not disclosed in available records, the company's focus on non-invasive chemical analysis of the brain places it within the broader medical device and diagnostic services landscape. The company's market capitalization and annual revenue figures are currently unlisted or unavailable, while the specific employee count is also not provided in the dataset. Without explicit market cap data to quantify its market position, the available revenue figure of $75,730 suggests a very small operational scale relative to large-cap healthcare peers. The absence of a stated market cap value indicates that the company may be trading on a thin volume or exists primarily as a pre-revenue entity in its current reporting cycle, which limits the ability to gauge its relative size against established competitors in the neuroimaging space.

财务健康

Aclarion reported a trailing twelve-month revenue of $75,730, yet this revenue generated a net loss of $7,240,312, revealing a substantial gap between top-line generation and profitability driven by significant operating expenses. The EBITDA for the period was negative at $-6,824,985, indicating that core operational cash earnings before interest, taxes, depreciation, and amortization are insufficient to cover costs. Free cash flow stands at $-4,634,310, which signifies a lack of immediate financial flexibility to fund operations or capital expenditures without external financing. Despite the severe losses, the company holds $12.03 million in cash and zero in debt, creating a unique balance sheet where liquidity vastly exceeds liabilities. The gross margin is recorded at 9.0%, suggesting a low-margin cost structure typical of early-stage technology development where cost of goods sold consumes most of revenue. Operating margin is reported as -10,785.2% and profit margin is 0.0%, figures that indicate extreme operational inefficiency or accounting adjustments relative to the tiny revenue base. The current ratio is an exceptionally high 14.81, demonstrating that the company possesses 14.81 times more current assets than current liabilities, pointing to robust short-term liquidity despite the lack of profitability. Return on equity is -104.8% and return on assets is -55.8%, metrics that reveal management is currently destroying shareholder value and utilizing assets to generate negative returns rather than positive growth.

估值评估

Trailing P/E and forward P/E ratios are unavailable due to the negative net income, meaning traditional earnings-based valuation multiples cannot be calculated to assess the stock's price relative to profitability. The price-to-book ratio is listed as 0.00, indicating that the market capitalization is effectively zero or negligible compared to the company's book value, which suggests the market does not assign significant premium value to the firm's assets. Price-to-sales and EV/EBITDA ratios are not calculable given the lack of market cap data and negative earnings, rendering these alternative valuation metrics inapplicable for standard comparison. The 52-week high and low are both recorded at $0.04, meaning the stock has not traded within a range and currently trades at 0.00% below the 52-week high as there is no premium to measure. A beta of 1.14 indicates that the stock's price volatility is 14% higher than the broader market, suggesting it experiences amplified price swings relative to the overall market index.

Growth & Income

Revenue growth year-over-year is reported at 80.6%, while earnings growth is not applicable due to the company's net loss, implying that top-line expansion is occurring without a corresponding improvement in profitability. Since the company does not pay dividends, there is no dividend yield or payout ratio to analyze for sustainability or reinvestment strategies. The absence of dividend payments confirms that the company retains all earnings, if any, or relies entirely on external capital to fund its operations and growth initiatives. The overall growth and income profile is characterized by high revenue expansion paired with deep losses and no income distribution to shareholders.